Q2 2026 Taysha Gene Therapies, Inc. Earnings Call Transcript
Key Points
- Completed dosing in both the REVEAL Pivotal and ASPIRE trials, with 17 and 4 patients respectively, supporting a broad label for Rett syndrome.
- Longer-term Part A data showed a 100% response rate at 12 months, far exceeding the FDA-aligned 33% efficacy threshold, with no plateau effect observed.
- Favorable safety profile across 33 treated patients, with no severe treatment-related serious adverse events or dose-limiting toxicities as of August 2026.
- Expanded partnership with Catalent for commercial manufacturing, securing long-term capacity at an FDA-licensed facility with BLA-enabling PPQ activities underway.
- Strengthened balance sheet with $455.4 million in cash, extending runway into the second half of 2028 and through potential BLA approval.
- Payer research indicated strong support for Taysha-102's value proposition, driven by its transformative potential and convenient intrathecal administration.
- Reported a grade 2 treatment-related serious adverse event of peripheral sensory neuropathy in a REVEAL Pivotal patient, requiring overnight hospitalization.
- R&D expenses increased significantly to $38.6 million in Q2 2026, up from $20.1 million in Q2 2025, due to manufacturing and clinical costs.
- Net loss widened to $46.6 million in Q2 2026, compared to $26.9 million in Q2 2025, reflecting higher operating expenses.
- The six-month interim analysis from the REVEAL Pivotal trial is not expected until the first half of 2027, leaving regulatory uncertainty for an extended period.
- The company faces potential challenges in managing AAV9-associated peripheral neuropathy risks, which may require ongoing monitoring and immunomodulatory interventions.
- Commercial launch readiness is still in early stages, with limited details on sales force size and go-to-market strategy, creating execution risk.
Hello, and welcome to the Taysha Gene Therapies Second Quarter 2026 Financial Results Conference Call.
At this time, all participants are in a listen-only mode.
After the speaker presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press *11 on your telephone. You will then hear an automated message advising your hand has been raised. To withdraw your question, please press *11 again. Please be advised that today's conference is being recorded.
It is now my pleasure to introduce Vice President of Corporate Communications and Investor Relations, Haley Collins.
Thank you. Good afternoon and welcome to Taisha.
2026 Financial Results and Corporate Update Conference Call.
Earlier today, Tayshia issued a press release announcing financial results for the quarter ended June 30th, 2026.
A copy of this press release is available on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
